Editorial
Dear Colleagues,
Since its inception in 2008, the Clinical Trials on Alzheimer’s Disease (CTAD) conference has established itself as the premier global meeting exclusively dedicated to clinical trials in Alzheimer’s Disease (AD) it is held annually at the end of the year either in Europe or in the USA.
We are pleased to announce the highly exclusive China CTAD Advanced Workshop and Course (CTAD AWC), taking place on September 6–7, 2025, in Shanghai, China.
This workshop will convene top leaders from China’s foremost Alzheimer’s research centers, alongside distinguished experts from Europe and the United States. It will serve as a platform to advance the CTAD Chinese Clinical Trials Centers Initiative and explore ways to collectively enhance clinical trial capabilities, accelerating the development of new therapeutic strategies for Alzheimer’s Disease.
The program will feature focused discussions on critical topics, including:
- AD Clinical Trials Results
- Newly approved therapies for Alzheimer’s Disease and return on experience.
- New biomarkers for AD Diagnostics.
- Vascular Contribution to AD.
- Exploring new avenues beyond amyloid-clearing treatments including:
- Breakthrough translational research.
- Innovative therapeutic approaches.
In addition, the CTAD Conference invites abstract submissions from leading Chinese research teams to share their work within these categories, further enriching the exchange of groundbreaking ideas.
As this workshop is limited in attendance, participation will be reserved for a select group of distinguished experts. We hope you will join us in this pioneering initiative, which seeks to strengthen academic and industrial collaboration in Alzheimer’s research. Together, we can make meaningful progress in the fight against this devastating disease, advancing the discovery of life-changing therapies and improving the lives of millions.
We look forward to welcoming you to this landmark event.
Yours faithfully,
CTAD Conference Management